scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.OPHTHA.2009.07.023 |
P698 | PubMed publication ID | 19969368 |
P2093 | author name string | Donald S Fong | |
Jin-Wen Hsu | |||
Jennifer Howes | |||
Peter Custis | |||
P433 | issue | 2 | |
P921 | main subject | macular degeneration | Q27429789 |
bevacizumab | Q413299 | ||
multicenter clinical trial | Q6934595 | ||
P304 | page(s) | 298-302 | |
P577 | publication date | 2009-12-06 | |
P1433 | published in | Ophthalmology | Q7098109 |
P1476 | title | Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study | |
P478 | volume | 117 |
Q84251275 | A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular |
Q92523288 | A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration |
Q37361023 | Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography. |
Q92480382 | Assessment of bevacizumab quality and stability in repackaged syringes for clinical use |
Q49176127 | Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population |
Q82063645 | Bevacizumab and Ocular Wound Healing After Primary Pterygium Excision |
Q35705156 | Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety |
Q37996922 | Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease |
Q41915161 | Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients |
Q34139793 | Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema |
Q35060360 | Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration |
Q35162123 | Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis |
Q35923834 | Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration |
Q36907322 | Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration |
Q38867052 | Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System |
Q42324331 | Exogenous group G Streptococcus endophthalmitis following intravitreal ranibizumab injection |
Q42734263 | Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration |
Q36596476 | Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia |
Q36596479 | Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait |
Q37792817 | Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications |
Q38764072 | Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies |
Q35641933 | Lasting controversy on ranibizumab and bevacizumab |
Q88391709 | Letter to the Editor |
Q35560661 | Medicare costs for neovascular age-related macular degeneration, 1994-2007. |
Q35127099 | Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration |
Q38477676 | Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy |
Q42770014 | Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. |
Q37570185 | Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study |
Q37801665 | Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration |
Q37550855 | Switching from intravitreal ranibizumab to bevacizumab for age-related macular degeneration |
Q38210239 | Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. |
Q26849299 | The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy |
Q39321127 | Therapeutic targeting of the angiopoietin-TIE pathway |
Q36770126 | Transforming care delivery through health information technology |
Search more.